<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: This paper describes the rationale and design of the ENVIS-ion Study, which aims to determine whether low-dose aspirin reduces the development of white matter hyper-intense (WMH) lesions and silent <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> (SBI) </plain></SENT>
<SENT sid="1" pm="."><plain>Additional aims include determining whether a) changes in <z:chebi fb="46" ids="15035">retinal</z:chebi> vascular imaging (RVI) parameters parallel changes in brain magnetic resonance imaging (MRI); b) changes in RVI parameters are observed with aspirin therapy; c) baseline cognitive function correlates with MRI and RVI parameters; d) changes in cognitive function correlate with changes in brain MRI and RVI and e) whether factors such as age, gender or blood pressure influence the above associations </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS/DESIGN: Double-blind, placebo-controlled trial of three years duration set in two Australian academic medical centre outpatient clinics </plain></SENT>
<SENT sid="3" pm="."><plain>This study will enrol 600 adults aged 70 years and over with <z:mpath ids='MPATH_458'>normal</z:mpath> cognitive function and without overt <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Subjects will undergo cognitive testing, brain MRI and RVI at baseline and after 3 years of study treatment </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> subjects will be recruited from a 19,000-patient clinical outcome trial conducted in Australia and the United States that will evaluate the effects of aspirin in maintaining disability-free longevity over 5 years </plain></SENT>
<SENT sid="6" pm="."><plain>The intervention will be aspirin 100 mg daily versus matching placebo, randomized on a 1:1 basis </plain></SENT>
<SENT sid="7" pm="."><plain>DISCUSSION: This study will improve understanding of the mechanisms at the level of brain and vascular structure that underlie the effects of aspirin on cognitive function </plain></SENT>
<SENT sid="8" pm="."><plain>Given the limited access and high cost of MRI, RVI may prove useful as a tool for the identification of individuals at high risk for the development of cerebrovascular disease and <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01038583 </plain></SENT>
</text></document>